PITTSBURGH, June 8 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Tablets, 150 mg.

Doxycycline Tablets are the generic version of Par Pharmaceutical's Doxycycline Tablets, 150mg, marketed as Adoxa^® Tablets by Doak Dermatologics. Doxycycline Tablets had U.S. sales of approximately $34 million for the 12 months ending March 31, 2007, for the 150 mg strength.

In addition to this new product strength, Mylan previously received approval and is marketing the 50 mg, 75 mg and 100 mg strengths of Doxycycline Tablets.

This product will be shipped immediately.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit www.mylan.com.

SOURCE Mylan Laboratories Inc.



CONTACT: Patrick Fitzgerald or Kris King of Mylan Laboratories Inc.,
+1-724-514-1800
Web site: http://www.mylan.com